TCI Biotech invests US$26M to expand North American powder, liquid and jelly sachet manufacturing
Key takeaways
- TCI Biotech is investing over US$26 million to upgrade its Utah, US, facility with new powder, liquid, and jelly sachet production lines.
- The expansion aims to localize the supply chain for the North American market, which currently accounts for 30% of the company’s total revenue.
- This investment includes plans to scale up clinical research and product development to support a double-digit growth trajectory in the US.
Global biotechnology specialist TCI Biotech has injected US$26.225 million in capital to expand its existing manufacturing facility in American Fork, Utah, US. Serving the North American market, the upgrade will roll out advanced equipment, producing its newly launched powder sachet production line.
The site is also designed to support future liquid and jelly sachet production, with the intention of enhancing its manufacturing flexibility and capacity.
Liquid sachets offer convenient, single-dose, ready-to-consume formats that improve product stability and the overall consumer experience, the manufacturer highlights.
Alongside these supply chain developments, the company plans to expand its clinical research and product development capabilities.
“This expansion represents not only a capacity upgrade, but also a significant milestone in strengthening the North American operational footprint and localized manufacturing capabilities,” states the company.
Progressive upgrades
Currently, the US market contributes approximately 30% of TCI Biotech’s overall revenue, according to the supplier.
.webp)
TCI Biotech’s manufacturing facility in American Fork, Utah, US (Image credit: TCI Biotech).As part of its long-term focus on the US market, the company says it will progressively introduce selected production processes to its Utah facility to advance a localized supply chain and operational efficiency.
TCI Biotech expects the US market to maintain a double-digit annual growth rate in the coming years, positioning the country as one of the company’s most important long-term growth engines.
The manufacturer currently operates across the US, China, the Netherlands, Japan, Thailand, India, Vietnam, and Indonesia. The company states that this global footprint enables it to access high-growth markets, shorten supply chain cycles, strengthen collaboration with partners worldwide, and reduce tariff and logistics costs.
“Through continued investment in US-based manufacturing and R&D, TCI Biotech aims to further enhance its global one-stop solution capabilities — from natural ingredient development and applied research to product design, production, market promotion, and distribution,” notes the supplier.
In previous upgrades, TCI Biotech opened its Advanced Performance Nutrition Research Center in Salt Lake City, Utah, US, last November. This innovation hub focuses on high-performance nutrition, cognitive wellness, healthy aging, and sports performance.
